4505 EMPEROR BOULEVARD, DURHAM, NC
Reports First Quarter 2026 Financial Results and Provides Business Update
Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
Annual Report to Security Holders
Reports Full Year 2025 Financial Results and Provides Business Update
Material Contracts, Completing Asset Acquisition or Sale, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Reg. FD
Amended material disclosure
Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
BioCryst Pharmaceuticals Increases ORLADEYO® Wholesale Acquisition Cost
FY 2024
Q3
Q2
Q1
FY 2023
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-4/A
Prospectus Filed Pursuant to Rule 425
S-4
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence
SEC Staff Correspondence